Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01768572 · ClinicalTrials.gov registry record · Phase 3
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)
A Phase 3 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 3
- Development phase
- 202
- Enrollment target
NCT01768572 is a Phase 3 study that has completed, run by Sanofi. The registered enrollment target is 202 participants.
The verdict
NCT01768572, a Phase 3 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 202 participants
- Enrollment target
Study Summary
Primary Objective: To assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.
Interventions
- DRUG methotrexate
- DRUG tocilizumab
- DRUG hydroxychloroquine
- DRUG sarilumab SAR153191 (REGN88)
- DRUG sulfasalazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 202 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01768572
The ClinicalTrials.gov registry entry for NCT01768572 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 202 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which methotrexate is the first listed.
NCT01768572 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01768572 about?
NCT01768572 is a clinical study titled "To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)". Primary Objective: To assess, in the same study, the safety of sarilumab and tocilizumab in participants with rheumatoid arthritis (RA) who were inadequate responders to or intolerant of tumor necrosis factor (TNF) antagonists.
What is the current status of trial NCT01768572?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 202 participants. The study started on 2013-03. Estimated completion is 2014-10.
What interventions are being tested in trial NCT01768572?
The interventions under investigation include: methotrexate (DRUG), tocilizumab (DRUG), hydroxychloroquine (DRUG), sarilumab SAR153191 (REGN88) (DRUG), sulfasalazine (DRUG).
Who is sponsoring clinical trial NCT01768572?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.